News & Updates

Show Multimedia Only
Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC

Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC

16 Aug 2023

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

16 Aug 2023
Modified-dose nirmatrelvir-ritonavir well tolerated, effective in advanced CKD patients

Modified-dose nirmatrelvir-ritonavir well tolerated, effective in advanced CKD patients

15 Aug 2023 byChristina Lau

Modified-dose regimens of nirmatrelvir-ritonavir are well tolerated and effective in COVID-19 patients with advanced chronic kidney disease (CKD), including those on dialysis, a study by the Chinese University of Hong Kong (CUHK) has shown.

15 Aug 2023
Metabolic syndrome carries increased risk of lung cancer

Metabolic syndrome carries increased risk of lung cancer

15 Aug 2023

Individuals with metabolic syndrome (MetS) have a heightened risk of incident lung cancer, with the risk increase especially pronounced in those with a higher number of metabolic abnormalities and in women, according to a study.

15 Aug 2023